-
Iron deficiency anemia as a risk factor of childhood asthma
Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud
Research Article: Clinical Investigation
-
Iron deficiency anemia as a risk factor of childhood asthma
Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud
Research Article: Clinical Investigation
-
Iron deficiency anemia as a risk factor of childhood asthma
Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud
Research Article: Clinical Investigation
-
Iron deficiency anemia as a risk factor of childhood asthma
Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud
Research Article: Clinical Investigation
-
Iron deficiency anemia as a risk factor of childhood asthma
Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud
Research Article: Clinical Investigation
-
Iron deficiency anemia as a risk factor of childhood asthma
Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud
Research Article: Clinical Investigation
-
Iron deficiency anemia as a risk factor of childhood asthma
Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud
Research Article: Clinical Investigation
-
Iron deficiency anemia as a risk factor of childhood asthma
Maghrib S AlKhateeb, Hassan M Khalil, Mezher M Kadhim, Jalil I Alezzi and Najdat Sh Mahmoud
Research Article: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Stefania Cerri, Cinzia Del Giovane, Sara Balduzzi, Francesco Soncini, Antonia Sdanganelli, Luca Richeldi
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Clinical trial identifies potential new treatments for infantile eczema
News and Views: Clinical Investigation
-
Clinical trial identifies potential new treatments for infantile eczema
News and Views: Clinical Investigation
-
Clinical trial identifies potential new treatments for infantile eczema
News and Views: Clinical Investigation
-
Clinical trial identifies potential new treatments for infantile eczema
News and Views: Clinical Investigation
-
Clinical trial identifies potential new treatments for infantile eczema
News and Views: Clinical Investigation
-
Clinical trial identifies potential new treatments for infantile eczema
News and Views: Clinical Investigation
-
Clinical trial identifies potential new treatments for infantile eczema
News and Views: Clinical Investigation
-
Clinical trial identifies potential new treatments for infantile eczema
News and Views: Clinical Investigation
-
Clinical innovation for neurodegenerative diseases
Olivier Blin, Ceri H Davies, Bai Lu
Editorial: Clinical Investigation
-
Clinical innovation for neurodegenerative diseases
Olivier Blin, Ceri H Davies, Bai Lu
Editorial: Clinical Investigation
-
Clinical innovation for neurodegenerative diseases
Olivier Blin, Ceri H Davies, Bai Lu
Editorial: Clinical Investigation
-
Clinical innovation for neurodegenerative diseases
Olivier Blin, Ceri H Davies, Bai Lu
Editorial: Clinical Investigation
-
Clinical innovation for neurodegenerative diseases
Olivier Blin, Ceri H Davies, Bai Lu
Editorial: Clinical Investigation
-
Clinical innovation for neurodegenerative diseases
Olivier Blin, Ceri H Davies, Bai Lu
Editorial: Clinical Investigation
-
Clinical innovation for neurodegenerative diseases
Olivier Blin, Ceri H Davies, Bai Lu
Editorial: Clinical Investigation
-
Clinical innovation for neurodegenerative diseases
Olivier Blin, Ceri H Davies, Bai Lu
Editorial: Clinical Investigation
-
Impact of recent landmark clinical trials on hypertension treatment
Ikechi G Okpechi, Brian L Rayner
Review Article: Clinical Investigation
-
Impact of recent landmark clinical trials on hypertension treatment
Ikechi G Okpechi, Brian L Rayner
Review Article: Clinical Investigation
-
Impact of recent landmark clinical trials on hypertension treatment
Ikechi G Okpechi, Brian L Rayner
Review Article: Clinical Investigation
-
Impact of recent landmark clinical trials on hypertension treatment
Ikechi G Okpechi, Brian L Rayner
Review Article: Clinical Investigation
-
Impact of recent landmark clinical trials on hypertension treatment
Ikechi G Okpechi, Brian L Rayner
Review Article: Clinical Investigation
-
Impact of recent landmark clinical trials on hypertension treatment
Ikechi G Okpechi, Brian L Rayner
Review Article: Clinical Investigation
-
Impact of recent landmark clinical trials on hypertension treatment
Ikechi G Okpechi, Brian L Rayner
Review Article: Clinical Investigation
-
Impact of recent landmark clinical trials on hypertension treatment
Ikechi G Okpechi, Brian L Rayner
Review Article: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation
-
Certolizumab pegol in the treatment of Crohns disease: evidence from the PRECiSE clinical trial program
Ian C Lawrance
Review Article: Clinical Investigation